Biomarker testing for oncology aims to identify genes, proteins, or tumor markers that are specific to the cancer. Understanding the biomarkers present in a certain cancer helps optimize therapeutic regimens and inform personalized medicine strategies.
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identif...
In this study, we evaluated the concordance of targeted sequencing results between paired ctDNA and tumor samples from early breast cancers scheduled for curative surgery with or without adj...
In this study, we evaluated the concordance of targeted sequencing results between paired ctDNA and tumor samples from early breast cancers scheduled for curative surgery with or without adj...
Date: August 24, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Next Generation Sequencing (NGS) has evolved rapidly since the first sequencing platforms were commercially released ne...
Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify potentially actionable genetic alterations and exploit the molecular...
High volume clinical MS proteomic evaluation of plasma samples enriched for exosomes offering a real-time and non-invasive perspective of changing maternal and fetal tissues....
In examining the potential adoption of the Oncomine Precision Assay, University of Texas Health had several criteria to consider, including the need for highly accurate detection of small sa...
New genomic technologies are changing the face of cancer care, as well as accelerating our biological understanding of cancer. Cris will summarise several parallel cancer initiatives in New...
Comprehensive genomic profiling (CGP) is advancing precision oncology research through simultaneous analysis of multiple biomarkers in a single next-generation sequencing (NGS) assay. In thi...
As NGS panels grow, test interpretation becomes more complex and time-consuming / With the explosion of NGS data, the need for consolidated databases with reliable and transparent curation a...
According to the American Cancer Society, in there were an estimated 110,070 new cases diagnosed and approximately 32,120 deaths from gynecologic cancers in the U.S. in 2018. Of the five mos...
Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. Discovery’s recently launched S...
Cell-free DNA (cfDNA) is a key analyte for liquid biopsy samples. Due to extremely low concentration and high degree of fragmentation, the extraction of cfDNA is technically challenging. Her...
Patient laboratory test results are significantly over-represented in electronic medical records, but significantly under-utilized in research. An important application of laboratory data is...
The opioid crisis has put significant strain on the healthcare system and resources, including the clinical laboratory which has seen significant increases in requests for urine drug screeni...
Point-of-care testing (POCT) is destined to play a much greater role in chronic disease diagnosis and management. Advanced POCT systems are being developed to deliver less costly and more ac...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identif...
In this study, we evaluated the concordance of targeted sequencing results between paired ctDNA and tumor samples from early breast cancers scheduled for curative surgery with or without adj...
In this study, we evaluated the concordance of targeted sequencing results between paired ctDNA and tumor samples from early breast cancers scheduled for curative surgery with or without adj...
Date: August 24, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Next Generation Sequencing (NGS) has evolved rapidly since the first sequencing platforms were commercially released ne...
Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify potentially actionable genetic alterations and exploit the molecular...
High volume clinical MS proteomic evaluation of plasma samples enriched for exosomes offering a real-time and non-invasive perspective of changing maternal and fetal tissues....
In examining the potential adoption of the Oncomine Precision Assay, University of Texas Health had several criteria to consider, including the need for highly accurate detection of small sa...
New genomic technologies are changing the face of cancer care, as well as accelerating our biological understanding of cancer. Cris will summarise several parallel cancer initiatives in New...
Comprehensive genomic profiling (CGP) is advancing precision oncology research through simultaneous analysis of multiple biomarkers in a single next-generation sequencing (NGS) assay. In thi...
As NGS panels grow, test interpretation becomes more complex and time-consuming / With the explosion of NGS data, the need for consolidated databases with reliable and transparent curation a...
According to the American Cancer Society, in there were an estimated 110,070 new cases diagnosed and approximately 32,120 deaths from gynecologic cancers in the U.S. in 2018. Of the five mos...
Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. Discovery’s recently launched S...
Cell-free DNA (cfDNA) is a key analyte for liquid biopsy samples. Due to extremely low concentration and high degree of fragmentation, the extraction of cfDNA is technically challenging. Her...
Patient laboratory test results are significantly over-represented in electronic medical records, but significantly under-utilized in research. An important application of laboratory data is...
The opioid crisis has put significant strain on the healthcare system and resources, including the clinical laboratory which has seen significant increases in requests for urine drug screeni...
Point-of-care testing (POCT) is destined to play a much greater role in chronic disease diagnosis and management. Advanced POCT systems are being developed to deliver less costly and more ac...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
